Pharmacometabolic effect of pirfenidone treatment in IPF detected by high resolution MALDI-FTICR imaging
Published: Sep 15, 2018
Abstract
Idiopathic pulmonary fibrosis is a fatal condition with limited life expectancy and response to therapies. Pirfenidone is an approved therapy for IPF, yet its mechanism of action is unknown. Using high resolution MALDI-FTICR-mass spectrometry imaging (MSI) we detected, visualized, and quantified in situ endogenous and exogenous metabolites in mice and humans with lung fibrosis, and assessed the effect of pirfenidone treatment. In total, 1402...
Paper Details
Title
Pharmacometabolic effect of pirfenidone treatment in IPF detected by high resolution MALDI-FTICR imaging
Published Date
Sep 15, 2018
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History